{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T18:49:04Z","timestamp":1793731744372,"version":"4.6.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"vor","delay-in-days":56,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000065","name":"U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["1R01NS096376"],"award-info":[{"award-number":["1R01NS096376"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["1R01NS112856"],"award-info":[{"award-number":["1R01NS112856"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P50CA221747"],"award-info":[{"award-number":["P50CA221747"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Glioblastoma (GBM) remains one of the deadliest primary brain tumors, with rapid recurrence and near-universal resistance to temozolomide (TMZ) limiting long-term survival. In this study, we identify a clinically actionable mechanism of resistance driven by the\n                    <jats:italic>LMNA<\/jats:italic>\n                    \u2013\n                    <jats:italic>PRKDC<\/jats:italic>\n                    axis, which enhances DNA repair and tumor cell survival following TMZ treatment. Using patient-derived xenograft models of recurrent GBM, we demonstrate that resistant tumors exhibit elevated\n                    <jats:italic>LMNA<\/jats:italic>\n                    expression and increased physical interaction with\n                    <jats:italic>PRKDC<\/jats:italic>\n                    , a central regulator of non-homologous end joining (NHEJ). This interaction accelerates the repair of TMZ-induced DNA lesions, contributing to therapeutic failure. Proteomic profiling and targeted immunoprecipitation revealed a distinct\n                    <jats:italic>LMNA<\/jats:italic>\n                    \u2013\n                    <jats:italic>PRKDC<\/jats:italic>\n                    \u2013associated DNA repair complex. Inhibition of\n                    <jats:italic>PRKDC<\/jats:italic>\n                    with the ATP-competitive inhibitor KU57788 reversed resistance, restoring TMZ sensitivity and impairing tumor growth in vivo. Single-cell RNA sequencing of primary and recurrent GBM specimens further identified\n                    <jats:italic>LMNA<\/jats:italic>\n                    \u2013\n                    <jats:italic>PRKDC<\/jats:italic>\n                    co-expression as a hallmark of treatment-resistant, glioma stem-like cell populations. Importantly, high\n                    <jats:italic>LMNA<\/jats:italic>\n                    \u2013\n                    <jats:italic>PRKDC<\/jats:italic>\n                    expression was associated with inferior survival outcomes in GBM patient cohorts. These results establish the\n                    <jats:italic>LMNA<\/jats:italic>\n                    \u2013\n                    <jats:italic>PRKDC<\/jats:italic>\n                    axis as a functional driver of TMZ resistance through enhanced DNA repair capacity in stem-like tumor subpopulations. Our findings support pharmacologic inhibition of\n                    <jats:italic>PRKDC<\/jats:italic>\n                    as a rational strategy to resensitize resistant GBM to standard chemotherapy and offer a foundation for future biomarker-driven clinical trials targeting DNA repair vulnerabilities in recurrent disease.\n                  <\/jats:p>","DOI":"10.1038\/s41419-025-08226-3","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T05:26:24Z","timestamp":1763702784000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["LMNA-PRKDC axis enhances DNA repair and promotes chemoresistance in glioblastoma"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9955-9848","authenticated-orcid":false,"given":"Miranda R.","family":"Saathoff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafal","family":"Chojak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca X.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasaan A.","family":"Kazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umme H.","family":"Faisal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5088-7805","authenticated-orcid":false,"given":"Jack M.","family":"Shireman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noah","family":"Drewes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheol H.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuesong","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sana A.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4164-8423","authenticated-orcid":false,"given":"Irene","family":"Lazanyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivani","family":"Baisiwala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. David","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8340-9992","authenticated-orcid":false,"given":"Craig M.","family":"Horbinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4795-0188","authenticated-orcid":false,"given":"Atique U.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,21]]},"reference":[{"key":"8226_CR1","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1001\/jama.2015.16669","volume":"314","author":"R Stupp","year":"2015","unstructured":"Stupp R, Taillibert S, Kanner AA, Kesari S, Steinberg DM, Toms SA, et al. Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial. JAMA. 2015;314:2535\u201343.","journal-title":"JAMA"},{"key":"8226_CR2","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New Engl J Med. 2005;352:987\u201396.","journal-title":"New Engl J Med"},{"key":"8226_CR3","doi-asserted-by":"publisher","first-page":"iii1","DOI":"10.1093\/neuonc\/noab200","volume":"23","author":"QT Ostrom","year":"2021","unstructured":"Ostrom QT, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS. CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2014\u20132018. Neuro-Oncol. 2021;23:iii1\u2013105.","journal-title":"Neuro-Oncol"},{"key":"8226_CR4","doi-asserted-by":"publisher","first-page":"168","DOI":"10.4161\/cc.9.1.10363","volume":"9","author":"S Quiros","year":"2010","unstructured":"Quiros S, Roos WP, Kaina B. Processing of O6-methylguanine into DNA double-strand breaks requires two rounds of replication whereas apoptosis is also induced in subsequent cell cycles. Cell Cycle. 2010;9:168\u201378.","journal-title":"Cell Cycle"},{"key":"8226_CR5","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa043331","volume":"352","author":"ME Hegi","year":"2005","unstructured":"Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. New Engl J Med. 2005;352:997\u20131003.","journal-title":"New Engl J Med"},{"key":"8226_CR6","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1215\/15228517-2008-090","volume":"11","author":"GJ Kitange","year":"2009","unstructured":"Kitange GJ, Carlson BL, Schroeder MA, Grogan PT, Lamont JD, Decker PA, et al. Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts. Neuro Oncol. 2009;11:281\u201391.","journal-title":"Neuro Oncol"},{"key":"8226_CR7","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1093\/neuonc\/nox142","volume":"20","author":"D Garnier","year":"2018","unstructured":"Garnier D, Meehan B, Kislinger T, Daniel P, Sinha A, Abdulkarim B, et al. Divergent evolution of temozolomide resistance in glioblastoma stem cells is reflected in extracellular vesicles and coupled with radiosensitization. Neuro Oncol. 2018;20:236\u201348.","journal-title":"Neuro Oncol"},{"key":"8226_CR8","doi-asserted-by":"publisher","first-page":"eade7236","DOI":"10.1126\/sciadv.ade7236","volume":"9","author":"EN Perrault","year":"2023","unstructured":"Perrault EN, Shireman JM, Ali ES, Lin P, Preddy I, Park C, et al. Ribonucleotide reductase regulatory subunit M2 drives glioblastoma TMZ resistance through modulation of dNTP production. Sci Adv. 2023;9:eade7236.","journal-title":"Sci Adv"},{"key":"8226_CR9","doi-asserted-by":"publisher","first-page":"5494","DOI":"10.3390\/cancers14225494","volume":"14","author":"M McCord","year":"2022","unstructured":"McCord M, Bartom E, Burdett K, Baran A, Eckerdt FD, Balyasnikova IV, et al. Modeling therapy-driven evolution of glioblastoma with patient-derived xenografts. Cancers. 2022;14:5494.","journal-title":"Cancers"},{"key":"8226_CR10","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1042\/BST20220741","volume":"51","author":"A Vogt","year":"2023","unstructured":"Vogt A, He Y, Lees-Miller SP. How to fix DNA breaks: new insights into the mechanism of non-homologous end joining. Biochem Soc Trans. 2023;51:1789\u2013800.","journal-title":"Biochem Soc Trans"},{"key":"8226_CR11","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.4161\/cc.10.15.16531","volume":"10","author":"AB Redwood","year":"2011","unstructured":"Redwood AB, Perkins SM, Vanderwaal RP, Feng Z, Biehl KJ, Gonzalez-Suarez I, et al. A dual role for A-type lamins in DNA double-strand break repair. Cell Cycle. 2011;10:2549\u201360.","journal-title":"Cell Cycle"},{"key":"8226_CR12","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1111\/acel.12258","volume":"14","author":"I Gibbs-Seymour","year":"2015","unstructured":"Gibbs-Seymour I, Markiewicz E, Bekker-Jensen S, Mailand N, Hutchison CJ. Lamin A\/C-dependent interaction with 53BP1 promotes cellular responses to DNA damage. Aging Cell. 2015;14:162\u20139.","journal-title":"Aging Cell"},{"key":"8226_CR13","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1093\/abbs\/gmw046","volume":"48","author":"K Yang","year":"2016","unstructured":"Yang K, Guo R, Xu D. Non-homologous end joining: advances and frontiers. Acta Biochim Biophys Sin. 2016;48:632\u201340.","journal-title":"Acta Biochim Biophys Sin"},{"key":"8226_CR14","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1093\/neuonc\/noae059","volume":"26","author":"S Budhiraja","year":"2024","unstructured":"Budhiraja S, McManus G, Baisiwala S, Perrault EN, Cho S, Saathoff M, et al. ARF4-mediated retrograde trafficking as a driver of chemoresistance in glioblastoma. Neuro Oncol. 2024;26:1421\u201337.","journal-title":"Neuro Oncol"},{"key":"8226_CR15","doi-asserted-by":"crossref","unstructured":"Ruiz-Moreno C, Salas SM, Samuelsson E, Brandner S, Kranendonk MEG, Nilsson M, et al. Harmonized single-cell landscape, intercellular crosstalk and tumor architecture of glioblastoma. bioRxiv; 2022. p. 2022.08.27.505439. Available from: https:\/\/www.biorxiv.org\/content\/10.1101\/2022.08.27.505439v1.","DOI":"10.1101\/2022.08.27.505439"},{"key":"8226_CR16","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1124\/mol.54.2.334","volume":"54","author":"S D\u2019Atri","year":"1998","unstructured":"D\u2019Atri S, Tentori L, Lacal PM, Graziani G, Pagani E, Benincasa E, et al. Involvement of the mismatch repair system in temozolomide-induced apoptosis. Mol Pharm. 1998;54:334\u201341.","journal-title":"Mol Pharm"},{"key":"8226_CR17","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2174\/156800909787314011","volume":"9","author":"PR Andreassen","year":"2009","unstructured":"Andreassen PR, Ren K. Fanconi anemia proteins, DNA interstrand crosslink repair pathways, and cancer therapy. Curr Cancer Drug Targets. 2009;9:101\u201317.","journal-title":"Curr Cancer Drug Targets"},{"key":"8226_CR18","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/nrd1984","volume":"5","author":"G Szak\u00e1cs","year":"2006","unstructured":"Szak\u00e1cs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2006;5:219\u201334.","journal-title":"Nat Rev Drug Discov"},{"key":"8226_CR19","doi-asserted-by":"publisher","DOI":"10.4061\/2010\/543531","volume":"2010","author":"N Kondo","year":"2010","unstructured":"Kondo N, Takahashi A, Ono K, Ohnishi T. DNA damage induced by alkylating agents and repair pathways. J Nucleic Acids. 2010;2010:543531.","journal-title":"J Nucleic Acids"},{"key":"8226_CR20","doi-asserted-by":"publisher","first-page":"7442","DOI":"10.3390\/jcm12237442","volume":"12","author":"B Kaina","year":"2023","unstructured":"Kaina B. Temozolomide, procarbazine and nitrosoureas in the therapy of malignant gliomas: update of mechanisms, drug resistance and therapeutic implications. J Clin Med. 2023;12:7442.","journal-title":"J Clin Med"},{"key":"8226_CR21","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.neo.2018.05.001","volume":"20","author":"MC de Gooijer","year":"2018","unstructured":"de Gooijer MC, de Vries NA, Buckle T, Buil LCM, Beijnen JH, Boogerd W, et al. Improved brain penetration and antitumor efficacy of temozolomide by inhibition of ABCB1 and ABCG2. Neoplasia. 2018;20:710\u201320.","journal-title":"Neoplasia"},{"key":"8226_CR22","doi-asserted-by":"publisher","first-page":"106510","DOI":"10.1016\/j.phrs.2022.106510","volume":"185","author":"L Radtke","year":"2022","unstructured":"Radtke L, Majchrzak-Celi\u0144ska A, Awortwe C, Vater I, Nagel I, Sebens S, et al. CRISPR\/Cas9-induced knockout reveals the role of ABCB1 in the response to temozolomide, carmustine and lomustine in glioblastoma multiforme. Pharmacol Res. 2022;185:106510.","journal-title":"Pharmacol Res"},{"key":"8226_CR23","doi-asserted-by":"publisher","first-page":"737","DOI":"10.3390\/genes13050737","volume":"13","author":"A Ali","year":"2022","unstructured":"Ali A, Xiao W, Babar ME, Bi Y. Double-stranded break repair in mammalian cells and precise genome editing. Genes. 2022;13:737.","journal-title":"Genes"},{"key":"8226_CR24","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1083\/jcb.200705106","volume":"179","author":"E Weterings","year":"2007","unstructured":"Weterings E, Chen DJ. DNA-dependent protein kinase in nonhomologous end joining: a lock with multiple keys? J Cell Biol. 2007;179:183\u20136.","journal-title":"J Cell Biol"},{"key":"8226_CR25","doi-asserted-by":"crossref","unstructured":"Yue X, Bai C, Xie D, Ma T, Zhou PK DNA-PKcs: A Multi-Faceted Player in DNA Damage Response. Front Genet. 2020;11. Available from: https:\/\/www.frontiersin.org\/journals\/genetics\/articles\/10.3389\/fgene.2020.607428\/full.","DOI":"10.3389\/fgene.2020.607428"},{"key":"8226_CR26","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1158\/0008-5472.CAN-21-1756","volume":"82","author":"E Dylgjeri","year":"2022","unstructured":"Dylgjeri E, Knudsen KE. DNA-PKcs: a targetable protumorigenic protein kinase. Cancer Res. 2022;82:523\u201333.","journal-title":"Cancer Res"},{"key":"8226_CR27","doi-asserted-by":"publisher","first-page":"5858","DOI":"10.1074\/jbc.273.10.5858","volume":"273","author":"EP Rogakou","year":"1998","unstructured":"Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139*. J Biol Chem. 1998;273:5858\u201368.","journal-title":"J Biol Chem"},{"key":"8226_CR28","doi-asserted-by":"publisher","first-page":"eabc7275","DOI":"10.1126\/scitranslmed.abc7275","volume":"13","author":"X Fang","year":"2021","unstructured":"Fang X, Huang Z, Zhai K, Huang Q, Tao W, Kim L, et al. Inhibiting DNA-PK induces glioma stem cell differentiation and sensitizes glioblastoma to radiation in mice. Sci Transl Med. 2021;13:eabc7275.","journal-title":"Sci Transl Med"},{"key":"8226_CR29","doi-asserted-by":"publisher","first-page":"2390","DOI":"10.1158\/0008-5472.CAN-03-3207","volume":"64","author":"T Stiff","year":"2004","unstructured":"Stiff T, O\u2019Driscoll M, Rief N, Iwabuchi K, L\u00f6brich M, Jeggo PA. ATM and DNA-PK function redundantly to phosphorylate H2AX after exposure to ionizing radiation. Cancer Res. 2004;64:2390\u20136.","journal-title":"Cancer Res"},{"key":"8226_CR30","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1101\/gad.1652708","volume":"22","author":"T Dechat","year":"2008","unstructured":"Dechat T, Pfleghaar K, Sengupta K, Shimi T, Shumaker DK, Solimando L, et al. Nuclear lamins: major factors in the structural organization and function of the nucleus and chromatin. Genes Dev. 2008;22:832\u201353.","journal-title":"Genes Dev"},{"key":"8226_CR31","first-page":"3005","volume":"127","author":"J Swift","year":"2014","unstructured":"Swift J, Discher DE. The nuclear lamina is mechano-responsive to ECM elasticity in mature tissue. J Cell Sci. 2014;127:3005\u201315.","journal-title":"J Cell Sci"},{"key":"8226_CR32","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/bs.apcsb.2024.06.002","volume":"143","author":"R Chauhan","year":"2025","unstructured":"Chauhan R, Gupta A, Dagar G, Sharma S, Sadida HQ, Hashem S, et al. Role of lamins in cellular physiology and cancer. Adv Protein Chem Struct Biol. 2025;143:119\u201353.","journal-title":"Adv Protein Chem Struct Biol"},{"key":"8226_CR33","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.3390\/biomedicines9101343","volume":"9","author":"G Gatti","year":"2021","unstructured":"Gatti G, Vilardo L, Musa C, Di Pietro C, Bonaventura F, Scavizzi F, et al. Role of Lamin A\/C as candidate biomarker of aggressiveness and tumorigenicity in glioblastoma multiforme. Biomedicines. 2021;9:1343.","journal-title":"Biomedicines"},{"key":"8226_CR34","first-page":"11709","volume":"47","author":"S Maynard","year":"2019","unstructured":"Maynard S, Keijzers G, Akbari M, Ezra MB, Hall A, Morevati M, et al. Lamin A\/C promotes DNA base excision repair. Nucleic Acids Res. 2019;47:11709\u201328.","journal-title":"Nucleic Acids Res"},{"key":"8226_CR35","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.3390\/cells12182299","volume":"12","author":"BH Kim","year":"2023","unstructured":"Kim BH, Chung YH, Woo TG, Kang SM, Park S, Park BJ. Progerin, an aberrant spliced form of Lamin A, is a potential therapeutic target for HGPS. Cells. 2023;12:2299.","journal-title":"Cells"},{"key":"8226_CR36","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/978-1-4899-8032-8_17","volume":"773","author":"S Gonzalo","year":"2014","unstructured":"Gonzalo S. DNA damage and lamins. Adv Exp Med Biol. 2014;773:377\u201399.","journal-title":"Adv Exp Med Biol"},{"key":"8226_CR37","doi-asserted-by":"publisher","first-page":"34045","DOI":"10.18632\/oncotarget.15973","volume":"8","author":"D Kinoshita","year":"2017","unstructured":"Kinoshita D, Nagasawa A, Shimizu I, Ito TK, Yoshida Y, Tsuchida M, et al. Progerin impairs vascular smooth muscle cell growth via the DNA damage response pathway. Oncotarget. 2017;8:34045\u201356.","journal-title":"Oncotarget"},{"key":"8226_CR38","doi-asserted-by":"publisher","first-page":"524","DOI":"10.3390\/biom2040524","volume":"2","author":"HL Ko","year":"2012","unstructured":"Ko HL, Ren EC. Functional aspects of PARP1 in DNA repair and transcription. Biomolecules. 2012;2:524\u201348.","journal-title":"Biomolecules"},{"key":"8226_CR39","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1093\/neuonc\/noab003","volume":"23","author":"S Wu","year":"2021","unstructured":"Wu S, Li X, Gao F, de Groot JF, Koul D, Yung WKA. PARP-mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O6-methylguanine DNA damage in glioblastoma. Neuro Oncol. 2021;23:920\u201331.","journal-title":"Neuro Oncol"},{"key":"8226_CR40","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1093\/neuonc\/noab269","volume":"24","author":"YA Yabo","year":"2022","unstructured":"Yabo YA, Niclou SP, Golebiewska A. Cancer cell heterogeneity and plasticity: a paradigm shift in glioblastoma. Neuro Oncol. 2022;24:669\u201382.","journal-title":"Neuro Oncol"},{"key":"8226_CR41","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1038\/cdd.2014.31","volume":"21","author":"B Auffinger","year":"2014","unstructured":"Auffinger B, Tobias AL, Han Y, Lee G, Guo D, Dey M, et al. Conversion of differentiated cancer cells into cancer stem-like cells in a glioblastoma model after primary chemotherapy. Cell Death Differ. 2014;21:1119\u201331.","journal-title":"Cell Death Differ"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08226-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08226-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08226-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T14:25:26Z","timestamp":1768573526000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08226-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8226"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-08226-3","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,21]]},"assertion":[{"value":"6 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All intracranial PDX experiments were approved by the Northwestern University IACUC (IS00004080 and IS00021383) and conducted in an AAALAC-accredited facility in accordance with the NIH Guide. For intracranial models, the maximal permitted tumor burden is defined by IACUC-approved humane endpoints. Mice were euthanized at the first occurrence of any endpoint, including \u226520% body-weight loss from baseline, body-condition score \u22642\/5, unrelieved or recurrent seizures, severe neurological deficit, inability to eat\/drink, or moribund state. These limits were not exceeded in any experiment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"50"}}